TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06122506

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cerclage
Description: Classic or robot-assisted laparoscopic cerclage in non-pregnant or early pregnant women.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal cerclage
Description: Transvaginal cerclage in pregnant women.
Study: NCT05280353

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glubran 2
Description: Application of Glubran 2 sealant (liquid) in axillary hollow
Study: NCT05870488

Intervention type: DEVICE
Group type: OTHER
Intervention: Use of iFuse TORQ
Description: Use of iFuse TORQ for the treatment of SI Joint dysfunction
Study: NCT05717400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velpatasvir
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxilaprevir
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Given by PO
Study: NCT06009094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC005
Description: VC005 group with Local topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC005
Description: VC005 group with Local topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC005
Description: VC005 group with Local topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC005
Description: VC005 group with Local topical application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VC005 Placebo
Description: VC005 Placebo group with Local topical application
Study: NCT06587490

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic ablative radiotherapy
Description: Stereotactic ablative radiotherapy is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumor, while limiting the dose to the surrounding organs.
Study: NCT04383327

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ParentCorps-Professional Development (PD)
Description: Multi-component school-based intervention that promotes early childhood mental health and development. Teachers and PTAs (pre-primary to 4th grade) will participate in a 3-day ParentCorps-PD training before the 1st school term. They will also receive 8 sessions (12 hours) of face-to-face group-based coaching during the 1st and 2nd terms. Coaching sessions are to help teachers apply EBI strategies in their classrooms, engage families, and develop competencies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ParentCorps-Professional Development (PD)
Description: Multi-component school-based intervention that promotes early childhood mental health and development. Teachers and PTAs (pre-primary to 4th grade) will participate in a 3-day ParentCorps-PD training before the 1st school term. They will also receive 8 sessions (12 hours) of face-to-face group-based coaching during the 1st and 2nd terms. Coaching sessions are to help teachers apply EBI strategies in their classrooms, engage families, and develop competencies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: T-Wellness
Description: A brief teacher stress management psychoeducation package, adapted from EBIs including a half-day workshop for common stress management and a half-day for burnout management, and three follow-up group support sessions (3 additional monthly 1-hr wellness sessions for teachers as a group in each school, a total 15 hours of coaching).
Study: NCT06618118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosigotifator
Description: Oral Use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Use
Study: NCT06719804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Oral administration is given solely for the epilepsy seizure event. Dosage: 20mg per dose; The patient's blood pressure and heart rate are monitored after the seizure; if the SBP is above 90 mmHg and the heart rate is above 60 beats per minute, then patients are instructed to take propranolol within 1 hour of a seizure . If the seizure frequency is excessively high, the interval between doses should be no less than 6 hours and the medication should not be administered more than 3 times a day.
Study: NCT06727435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non-sedation strategy
Description: Patients eligible for this study will undergo non-sedation strategy, which continuous analgesia without sedation is performed with remifentanil. The remifentanil will be titrated (from 0.1µg/kg/min to 0.2ug/kg/min) every 10-15 minutes to achieve the goal for sedation (RASS score maintaining -2 to + 1). The patients in the non-sedation trial do not receive any sedatives but could receive bolus doses (2.5 or 5mg) of morphine for analgesia.
Study: NCT06725316

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4-7-8 breathing exercises
Description: Steps of doing 4-7-8 breathing exercise; firstly, the breath taken is exhaled completely through the mouth as if whistling. Then the lips are closed and inhaled quietly through the nose (4 seconds). The breath is held for seven seconds. At the last stage, the lips are tightened and exhaled through the mouth for 8 seconds. Then normal breathing is done for one minute. Breathing is repeated four times every hour.
Study: NCT06725914

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: kangaroo care
Description: Transport practice with paternal kangaroo care in preterm infants
Study: NCT06725264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: 6 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: 6 mg twice daily
Study: NCT06726421

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Description: The preferred treatment plan is SBRT with a fraction dose ≥7 Gy. The prescription dose should ensure a BED of no less than 115. Radiotherapy is usually delivered daily, every other day, or other interval decided by treating radiation oncologist.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib
Description: Standard systemic therapy are targeted agents or their combination with immunotherapy recommended by guidelines. This may include axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib, etc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib
Description: Standard systemic therapy are targeted agents or their combination with immunotherapy recommended by guidelines. This may include axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib, etc.
Study: NCT06725589

Intervention type: OTHER
Intervention: metabolic disease
Description: metabolic disease
Study: NCT06727344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction
Description: Exercise with restriction of blood flow supply

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brace
Description: Knee brace to restrict range of motion

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Brace
Description: Knee brace to restrict range of motion
Study: NCT06725758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-212
Description: ODM-212 5mg and/or 40mg tablets
Study: NCT06725745

Intervention type: OTHER
Intervention: Survey
Description: Survey containing a primary survey regarding basic demographic features, medical treatment and organization of care and two validated questionnaires.
Study: NCT06726005

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: functional appliance twin block
Description: 3D facial scans will be taken (prior to the treatment, at rest and at mandible moved forward to class I dental relation (Fraenkel manouver)) and at the end of treatment, one year later.
Study: NCT06725056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DS-MCE and EGD examinations
Description: sequentially performing DS-MCE and EGD examinations on AUGIB patients with stable hemodynamics
Study: NCT06725511

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opt-out framing
Description: Outreach notifies those eligible that they are enrolled in the program and invites them to start participating.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Opt-in framing
Description: Eligible participants are invited to enroll
Study: NCT06726083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Intervention
Description: Weekly virtual live group sessions led by a trained study team member will be held twice weekly for 1 hour/week over 12 weeks using a HIPAA compliant online platform. The first class of each week will include the teaching kitchen cooking demonstration (\~30 min) and the remainder of the class will focus on dietary education. The second class each week will provide an opportunity for group discussion to have Veterans share to their peers about how they used the weekly produce

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contact Control
Description: Weekly virtual live group health education sessions led by staff will be held for two hours/week over 12 weeks. We will enroll up to 15 participants into each virtual class cohort and run multiple different group sessions for a total sample size of 90 participants. The content follows the LIFE study structured successful aging health education curriculum80,81 which was designed to increase self-efficacy and empower older Veterans to take control of their own healthcare. Topics focus on a broad range of healthy aging, such as importance of sleep, safe travel, goal setting, self-care, and common comorbidities
Study: NCT06725550

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: needling acupuncture
Description: Acupuncture treatment will both main and supplementary acupoints. Main points include GB30; ST36; LI11- LI4, GB34-SP6; LR3, SP10, DU24, DU20, Yin Tang, Ear Shen Men which are chosen based on the unique clinical features of sickle pain. The remaining individualized acupoints will be selected and manipulated with manual acupuncture with appropriate needling techniques based on the individual Syndrome (reinforce or reduce or Non reinforce or reduce) that is determined by TCM diagnosis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: needling acupuncture
Description: Acupuncture treatment will both main and supplementary acupoints. Main points include GB30; ST36; LI11- LI4, GB34-SP6; LR3, SP10, DU24, DU20, Yin Tang, Ear Shen Men which are chosen based on the unique clinical features of sickle pain. The remaining individualized acupoints will be selected and manipulated with manual acupuncture with appropriate needling techniques based on the individual Syndrome (reinforce or reduce or Non reinforce or reduce) that is determined by TCM diagnosis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser acupuncture
Description: Laser acupuncture device VitaLaser 650 (Lhasa OMS, Weymouth, MA or similar) will be positioned 1-2cm over all of the same acupoints used in verum acupuncture treatment above. No palpation is administered prior to positioning the device and there is no physical contact between device and skin.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser acupuncture
Description: Laser acupuncture device VitaLaser 650 (Lhasa OMS, Weymouth, MA or similar) will be positioned 1-2cm over all of the same acupoints used in verum acupuncture treatment above. No palpation is administered prior to positioning the device and there is no physical contact between device and skin.
Study: NCT06725641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test preparation：Methylcholine chloroacetate for inhalation
Description: Cholinergic agonists

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference preparation：Methylcholine chloroacetate for inhalation（Provocholine）
Description: Cholinergic agonists
Study: NCT05892328

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Watermelon Flesh Dose 1
Description: 1 cup watermelon flesh, \~152g, 7 days/week over a 4-week period

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Watermelon Flesh Dose 2
Description: 2 cups watermelon flesh, \~304 g, 7 days/week over a 4-week period

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 304g italian ice, 0 g watermelon, 7 days/week over a 4-week period
Study: NCT04718792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: A single administration of PEX010 (psilocybin 25 mg, opaque capsule for oral ingestion). PEX010 contains psilocybin (25 mg) naturally extracted from Psilocybe cubensis mushroom fruiting bodies, manufactured under current Good Manufacturing Practices (cGMP)
Study: NCT06358768

Intervention type: OTHER
Intervention: teamwork job improvement overall
Description: increase of teamwork capacities and skills improvement

Intervention type: OTHER
Intervention: teamwork job improvement overall
Description: increase of teamwork capacities and skills improvement
Study: NCT05732610

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MGC Health COVID-19 & Flu A+B Home Multi Test
Description: self-collected direct anterior nares swab samples

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MGC Health COVID-19 & Flu A+B Home Multi Test (2 to 13 y/o)
Description: adult lay user collected anterior nares swab sample
Study: NCT06358768

Intervention type: OTHER
Intervention: teamwork job improvement overall
Description: increase of teamwork capacities and skills improvement

Intervention type: OTHER
Intervention: teamwork job improvement overall
Description: increase of teamwork capacities and skills improvement

Intervention type: OTHER
Intervention: teamwork job improvement in actor scenario vs mannequin scenario
Description: increase of teamwork capacities and skills improvement. Comparison within different roles and different scenario learning

Intervention type: OTHER
Intervention: teamwork job improvement in actor scenario vs mannequin scenario
Description: increase of teamwork capacities and skills improvement. Comparison within different roles and different scenario learning

Intervention type: OTHER
Intervention: teamwork job improvement in actor scenario vs mannequin scenario
Description: increase of teamwork capacities and skills improvement. Comparison within different roles and different scenario learning

Intervention type: OTHER
Intervention: teamwork job improvement in actor scenario vs mannequin scenario
Description: increase of teamwork capacities and skills improvement. Comparison within different roles and different scenario learning

Intervention type: OTHER
Intervention: teamwork job improvement in actor scenario vs mannequin scenario
Description: increase of teamwork capacities and skills improvement. Comparison within different roles and different scenario learning
Study: NCT05557201

Intervention type: BIOLOGICAL
Intervention: Lymphocyte immunophenotyping
Description: If the patient accepts the ancillary study, a blood sample will be taken (1 EDTA tube of 3 ml and 2 lithium heparin tubes of 10 mL each) for lymphocyte immunophenotyping in flow cytometry on fresh blood and for the constitution of the biological collection (plasma/mononuclear cells).
Study: NCT06263933

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Insight Scale
Description: Before the patient was in DIPEM or control group and after the patient is involved in DIPEM or control group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insight Scale
Description: Before the patient was in DIPEM or control group and after the patient is involved in DIPEM or control group
Study: NCT04936126

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Quetiapine XR 100 mg/day augmentation to the ongoing Sertraline treatment for the study period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Description: Amantadine 200 mg/day (in two divided doses) augmentation to the ongoing Sertraline treatment for the study period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole
Description: Pramipexole 0.375 mg/day (in three divided doses) augmentation to the ongoing Sertraline treatment for the study period
Study: NCT04661917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2327949
Description: 60 mg of BAY2327949 (2 tablets of 30 mg, orally) once daily for 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo orally once daily for 28 days.
Study: NCT05031065

Intervention type: RADIATION
Intervention: Breast Cancer Radiotherapy
Description: 4000-4250 cGy in 15-16 daily fractions
Study: NCT05032651

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: novel artificial intelligence assisted platform
Description: Use of a novel artificial intelligence assisted platform

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: novel artificial intelligence assisted platform
Description: Use of a novel artificial intelligence assisted platform
Study: NCT04175938

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wearing of contact lens
Description: All subjects will wear a contact lens for three hours. The effect of the lens on the eye (epithelial swelling) will be measured at intervals after the lens is removed.

Intervention type: DEVICE
Group type: OTHER
Intervention: Wearing of contact lens
Description: All subjects will wear a contact lens for three hours. The effect of the lens on the eye (epithelial swelling) will be measured at intervals after the lens is removed.
Study: NCT05798624

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound between 6+0 and 6+7 weeks of pregnancy - With Isthmocele
Description: Location of implantation of the GS (gestational sac) amended to Naji et al, defined as 3 possible implantation sites: (A: fundal, B: anterior, C: posterior)~Size of isthmocele:~* Depth of isthmocele~* Width of isthmocele~* Circumference of isthmocele~Distance between isthmocele and outer cervical os (measured with the trace line) Distance between CS scar and outer cervical os (measured with the trace line) Size of gestational sac Measurements of the isthmocele size / circumference / distance between isthmocele / CS and outer cervical os

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound between 6+0 and 6+7 weeks of pregnancy - With Isthmocele
Description: Location of implantation of the GS (gestational sac) amended to Naji et al, defined as 3 possible implantation sites: (A: fundal, B: anterior, C: posterior)~Size of isthmocele:~* Depth of isthmocele~* Width of isthmocele~* Circumference of isthmocele~Distance between isthmocele and outer cervical os (measured with the trace line) Distance between CS scar and outer cervical os (measured with the trace line) Size of gestational sac Measurements of the isthmocele size / circumference / distance between isthmocele / CS and outer cervical os

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound between 6+0 and 6+7 weeks of pregnancy - Without Isthmocele
Description: Location of implantation of the GS amended to Naji et al, defined as 3 possible implantation sites: (A: fundal, B: anterior, C: posterior) Distance between CS scar and outer cervical os (measured with the trace line) Size of gestational sac
Study: NCT05371912

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trans Cranial Magnetic Stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neurostimulation technique that alters cortical excitability by repeated induction of electromagnetic activity. FDA approved for depression, rTMS is a promising tool in the field of neuropsychiatry with an excellent safety profile.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trans Cranial Magnetic Stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neurostimulation technique that alters cortical excitability by repeated induction of electromagnetic activity. FDA approved for depression, rTMS is a promising tool in the field of neuropsychiatry with an excellent safety profile.
Study: NCT05533424

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: quadratus lumborum
Description: the patient will be positioned supine with lateral tilt , and the transducer was placed at the level of the anterior superior iliac spine and moved cranially until the three abdominal wall muscles were clearly identified. The external oblique muscle was followed posterolaterally until its posterior border was visualized . The probe was tilted down to identify a bright hyperechoic line that represented the middle layer of the thoracolumbar fascia. The needle will be inserted in plane from anterolateral to posteromedial. The needle tip was placed between the thoracolumbar fascia and the QL muscle, and after negative aspiration, the correct position of the needle was proved by injection of 5 mL of normal saline to confirm the space with a hypoechoic image and hydrodissection. An injection of 20 mL of 0.25% bupivacaine was applied

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: transversus abdominis plane
Description: the probe will located between the iliac crest and the lower costal margin in the anterior axillary line at the level of umbilicus, and the layers of abdominal wall were identified (external oblique, internal oblique, and transverse abdominis muscles). In-plane technique was used and the tip of the needle was inserted between the internal oblique and transverse abdominis muscles. After negative aspiration (to exclude intravascular injection), 20 mL of 0.25% bupivacaine was injected. The same technique will be performed on the other side
Study: NCT04673578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Selective COX-2 inhibitor; nonsteroidal anti-inflammatory drug (NSAID)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose
Study: NCT06267222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRANSCRANIAL DIRECT CURRENT STIMULATION + exercises
Description: Participants with SCA will receive trans-spinal tDCS and exercises. There will be no control group or sham stimulation. All participants will receive real tDCS stimulation
Study: NCT05476016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near-infrared (NIR)
Description: NIR spectral assessment of glycated nail keratin vs HbA1c
Study: NCT06323252

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MastihaOil
Description: 1 soft gel capsule of Mastiha oil every day for 3 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nutritional counsel
Description: nutritional counsel